Get the Stockscreener App
2.92
7.75%
0.21
Black Diamond Therapeutics Inc stock is traded at $2.92, with a volume of 1.45M.
It is up +7.75% in the last 24 hours and down -8.46% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$2.71
Open:
$2.74
24h Volume:
1.45M
Relative Volume:
1.36
Market Cap:
$166.25M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-1.5532
EPS:
-1.88
Net Cash Flow:
$-66.75M
1W Performance:
+5.80%
1M Performance:
-8.46%
6M Performance:
+35.19%
1Y Performance:
-52.29%
1-Day Range:
$2.74
$3.041
1-Week Range:
$2.56
$3.041
52-Week Range:
$1.195
$6.66
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.92 | 156.57M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year? - sharewise.com
Black Diamond Therapeutics And 2 Promising Penny Stocks For Savvy Investors - Yahoo Finance
Do Its Financials Have Any Role To Play In Driving Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Stock Up Recently? - simplywall.st
Black Diamond Therapeutics Inc. Building a Base Near Support2025 Breakouts & Breakdowns & Long-Term Growth Stock Strategies - kangso.co.kr
Will Black Diamond Therapeutics Inc. stock go up soonOptions Play & Verified Momentum Stock Watchlist - Newser
Published on: 2025-08-17 21:53:04 - Newser
Recovery Signals Appearing in Black Diamond Therapeutics Inc. Charts2025 Buyback Activity & AI Powered Trade Plan Recommendations - sundaytimes.kr
Is Black Diamond Therapeutics Inc. Forming a Consolidation BaseJuly 2025 Reactions & Safe Swing Trade Setup Alerts - metal.it
Will Black Diamond Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsWeekly Risk Summary & Weekly High Potential Stock Alerts - Newser
Predicting Black Diamond Therapeutics Inc. trend using moving averagesChart Signals & High Accuracy Swing Trade Signals - Newser
How to use a screener to detect Black Diamond Therapeutics Inc. breakouts2025 Biggest Moves & Safe Swing Trade Setups - Newser
Elliott Wave Theory Predicts Pullback in Black Diamond Therapeutics Inc.July 2025 Rallies & High Conviction Buy Zone Alerts - metal.it
Published on: 2025-08-16 21:08:00 - Newser
Competitive Positioning of Black Diamond Therapeutics Inc.: Is It Leading or LaggingDay Trade & Community Consensus Trade Alerts - Newser
Has Black Diamond Therapeutics Inc. formed a bullish divergenceLong Setup & Accurate Entry/Exit Alerts - Newser
Machine Learning Models Forecast Black Diamond Therapeutics Inc. UptickWeekly Trend Recap & AI Enhanced Trade Execution Alerts - 선데이타임즈
Tick level data insight on Black Diamond Therapeutics Inc. volatilityWeekly Market Outlook & Momentum Based Trading Ideas - Newser
Should you wait for a breakout in Black Diamond Therapeutics Inc.July 2025 Fed Impact & Long-Term Safe Investment Ideas - Newser
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Sold by XTX Topco Ltd - Defense World
Price action breakdown for Black Diamond Therapeutics Inc.Index Update & Reliable Price Breakout Alerts - Newser
Chart based analysis of Black Diamond Therapeutics Inc. trendsQuarterly Investment Review & Capital Efficient Trade Techniques - Newser
Brokers Set Expectations for BDTX Q3 Earnings - Defense World
Black Diamond (BDTX) Q2 Loss Narrows 47% - AOL.com
Analysts Offer Predictions for BDTX FY2026 Earnings - Defense World
What moving averages say about Black Diamond Therapeutics Inc.Earnings Risk Report & Real-Time Volume Spike Alerts - Newser
Will Breakout in Black Diamond Therapeutics Inc. Sustain Through Next Week2025 Institutional Moves & Consistent Profit Alerts - metal.it
HC Wainwright Has Lowered Expectations for Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price - Defense World
Why Black Diamond Therapeutics Inc. stock attracts strong analyst attentionPrice Movement and Market Sentiment Analysis - Newser
Top Risks to Consider Before Buying Black Diamond Therapeutics Inc. StockInstitutional Holding Behavior Pattern Analysis - Newser
Black Diamond Therapeutics Reports Strong Financial Turnaround - TipRanks
Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise - MSN
What makes Black Diamond Therapeutics Inc. stock price move sharplyDaily Pattern Analysis with Return Forecast - Newser
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Cuts Target Price to $10 - 富途牛牛
H.C. Wainwright lowers Black Diamond Therapeutics stock price target on delayed launch - Investing.com Canada
Published on: 2025-08-11 06:28:53 - Newser
Black Diamond:HC Wainwright lowers PT to $10 from $12, maintains Buy rating. - AInvest
News impact scoring models applied to Black Diamond Therapeutics Inc.Fundamental Forecast for Undervalued Stocks - Newser
When is the best time to exit Black Diamond Therapeutics Inc.Momentum Trend Signal Weekly Recap Summary - Newser
Is Black Diamond Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Weekly Hot Picks With Buy Confidence - Newser
Black Diamond Therapeutics (NASDAQ:BDTX) Downgraded by Wall Street Zen to “Hold” - Defense World
Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Yahoo Finance
Black Diamond Therapeutics Reports Q2 Earnings with $45.98M Net Income and $70M Upfront Payment from Servier Agreement - AInvest
Black Diamond Therapeutics Maintains Buy Rating with $11 Price Target - AInvest
Black Diamond Therapeutics Slims Losses And Stays Flush With Cash - Finimize
Historical volatility pattern of Black Diamond Therapeutics Inc. visualizedFree Daily Chart Pattern Stock Forecast - Newser
Black Diamond Therapeutics Cuts Losses And Eyes Silevertinib Growth - Finimize
Black Diamond Therapeutics shares rise 1.75% premarket after reporting a narrower Q2 net loss and exploring partnerships for silevertinib development. - AInvest
Black Diamond: Q2 Earnings Snapshot - Stamford Advocate
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Black Diamond Therapeutics Inc Stock (BDTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Aug 28 '24 |
Sale |
6.32 |
221,600 |
1,400,556 |
3,726,341 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):